Drug Trial Radar · NCT07753850
A Study of SL-325 in Crohn's Disease Patients
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
232
Planned (sponsor's estimate)
Start
Nov 9, 2026
Primary completion
Jul 2028
Study completion Jun 2030
Sponsor
- Lead sponsor
- Shattuck Labs, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with moderate to severely active Crohn's disease. The study consists of a screening period of up to 6 weeks, a 12-week induction period, 38-week maintenance period, 52-week long-term extension period, and a 10-week follow-up period.
Conditions
- Crohn's Disease
Interventions
SL-325Drug
SL-325 administered intravenously
PlaceboDrug
Placebo administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who achieve endoscopic responseTime frame: Week 12
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Clinical Trial Site
Little Rock, Arkansas · Not yet recruiting
Clinical Trial Site
Oxnard, California · Not yet recruiting
Clinical Trial Site
Temple City, California · Not yet recruiting
Clinical Trial Site
West Hills, California · Not yet recruiting
Clinical Trial Site
Inverness, Florida · Not yet recruiting
Clinical Trial Site
Kissimmee, Florida · Recruiting
Clinical Trial Site
Naples, Florida · Not yet recruiting
Clinical Trial Site
Orlando, Florida · Not yet recruiting
Clinical Trial Site
Tampa, Florida · Not yet recruiting
Clinical Trial Site
Kansas City, Kansas · Not yet recruiting
Clinical Trial Site
Houma, Louisiana · Recruiting
Clinical Trial Site
Marrero, Louisiana · Not yet recruiting
Clinical Trial Site
Glen Burnie, Maryland · Not yet recruiting
Clinical Trial Site
Boston, Massachusetts · Not yet recruiting
Clinical Trial Site
Liberty, Missouri · Not yet recruiting
Clinical Trial Site
St Louis, Missouri · Not yet recruiting
Clinical Trial Site
Maspeth, New York · Not yet recruiting
Clinical Trial Site
Cincinnati, Ohio · Not yet recruiting
Clinical Trial Site
Columbus, Ohio · Not yet recruiting
Clinical Trial Site
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.